Evidence map›Paper›PMID 36835377›Full record

ArticleInternational journal of molecular sciences2023

Expression of the Calcitonin Receptor-like Receptor (CALCRL) in Normal and Neoplastic Tissues.

Benjamin Wende, Anna-Sophia Liselott Beyer, Niklas Ruhnke, Daniel Kaemmerer, Jörg Sänger, Stefan Schulz, Amelie Lupp

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Benjamin WendeInstitute of Pharmacology and Toxicology, Jena University Hospital, 07747 Jena, Germany.
Anna-Sophia Liselott BeyerInstitute of Pharmacology and Toxicology, Jena University Hospital, 07747 Jena, Germany.
Niklas RuhnkeInstitute of Pharmacology and Toxicology, Jena University Hospital, 07747 Jena, Germany.
Daniel KaemmererDepartment of General and Visceral Surgery, Zentralklinik Bad Berka, 99438 Bad Berka, Germany.
Jörg SängerLaboratory of Pathology and Cytology Bad Berka, 99438 Bad Berka, Germany.
Stefan SchulzInstitute of Pharmacology and Toxicology, Jena University Hospital, 07747 Jena, Germany.ORCID 0000-0002-5997-8885
Amelie LuppInstitute of Pharmacology and Toxicology, Jena University Hospital, 07747 Jena, Germany.ORCID 0000-0003-0141-7310
Jena University Hospital · DEZentralklinik Bad Berka · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Little information is available concerning protein expression of the calcitonin receptor-like receptor (CALCRL) at the protein level. Here, we developed a rabbit monoclonal antibody, 8H9L8, which is directed against human CALCRL but cross-reacts with the rat and mouse forms of the receptor. We confirmed antibody specificity via Western blot analyses and immunocytochemistry using the CALCRL-expressing neuroendocrine tumour cell line BON-1 and a CALCRL-specific small interfering RNA (siRNA). We then used the antibody for immunohistochemical analyses of various formalin-fixed, paraffin-embedded specimens of normal and neoplastic tissues. In nearly all tissue specimens examined, CALCRL expression was detected in the capillary endothelium, smooth muscles of the arterioles and arteries, and immune cells. Analyses of normal human, rat, and mouse tissues revealed that CALCRL was primarily present in distinct cell populations in the cerebral cortex; pituitary; dorsal root ganglia; epithelia, muscles, and glands of the larger bronchi; intestinal mucosa (particularly in enteroendocrine cells); intestinal ganglia; exocrine and endocrine pancreas; arteries, capillaries, and glomerular capillary loops in the kidneys; the adrenals; Leydig cells in the testicles; and syncytiotrophoblasts in the placenta. In the neoplastic tissues, CALCRL was predominantly expressed in thyroid carcinomas, parathyroid adenomas, small-cell lung cancers, large-cell neuroendocrine carcinomas of the lung, pancreatic neuroendocrine neoplasms, renal clear-cell carcinomas, pheochromocytomas, lymphomas, and melanomas. In these tumours with strong expression of CALCRL, the receptor may represent a useful target structure for future therapies.

Indexed as

Calcitonin Receptor-Like ProteinNeoplasmsAdrenomedullinAnimalsArteriesHumansIntestinal MucosaIntestinesMaleMiceRatsAdrenomedullinCalcitonin Receptor-Like ProteinCALCRL protein, humanadrenomedullinadrenomedullin receptoramylinamylin receptorantibodycalcitonin gene-related peptidecalcitonin gene-related peptide receptorcalcitonin receptor-like receptorimmunohistochemistryreceptor activity-modifying proteintumours

Identifiers

PMID36835377
PMCPMC9962437
OpenAlexW4321097761

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.